Keyword: Ninlaro

The Takeda-Shire deal passes investors; Sun suffers from a long list of allegations; J&J and Legend update CAR-T data.

Three years after its initial approval, Takeda’s Ninlaro may finally be ready to jump into a new indication.

Seventeen cancer drugs from global and local drugmakers take an average 56.7% discount to win spots on China's insurance scheme.

Takeda's $585 million Chinese revenue for FY2017 was only one-tenth of what it collected from Japan, and buying Shire won't change that soon.

Takeda expects Velcade sales to drop more than 30% this year, but it's hoping newer drugs Ninlanro and Entyvio help fill the gap.

Lilly will close its Shanghai R&D center, OrbiMed sets up its third Asia healthcare fund, and Takeda marches into CAR-T with a new deal.

Takeda's CEO has said Ninlaro would surpass blockbuster Velcade as the company’s biggest-ever cancer product. But NICE could get in the way.

Takeda's blockbuster cancer med Velcade, previously set for copycat competition this year, won an appeals court ruling preserving sales for years.

With a patent loss looming, Takeda filed a citizen petition pushing the FDA to knock back generic Velcade competition.